Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   41018   clinical trials with a EudraCT protocol, of which   6709   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2016-001651-49
    Sponsor's Protocol Code Number:ALX0171-C201
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-08-23
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-001651-49
    A.3Full title of the trial
    A randomized, double-blind, placebo-controlled, multicenter dose ranging study of ALX-0171 in infants and young children hospitalized for respiratory syncytial virus lower respiratory tract infection
    Estudio aleatorizado, en doble ciego, controlado con placebo y multicéntrico, de búsqueda de dosis de ALX-0171 en lactantes y niños de corta edad hospitalizados por infecciones del tracto respiratorio inferior por el virus respiratorio sincitial.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase 2b dose-ranging study of ALX-0171 in infants and young children hospitalized for RSV lower respiratory tract infection
    Estudio fase 2b de búsqueda de dosis de ALX-0171 en lactantes y niños de corta edad hospitalizados por infecciones del tracto respiratorio inferior por el virus respiratorio sincitial (RVS)
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code numberALX0171-C201
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/246/2014
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAblynx NV
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAblynx NV
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAblynx NV
    B.5.2Functional name of contact pointclinicaltrials@ablynx.com
    B.5.3 Address:
    B.5.3.1Street AddressTechnologiepark 21
    B.5.3.2Town/ cityZwijnaarde
    B.5.3.3Post code9052
    B.5.4Telephone number+32(0)9262 00 00
    B.5.5Fax number+32(0)9262 00 35
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameALX-0171 Nanobody
    D.3.2Product code ALX-0171
    D.3.4Pharmaceutical form Nebuliser solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnot assigned yet
    D.3.9.1CAS number not assigned
    D.3.9.2Current sponsor codeALX-0171
    D.3.9.3Other descriptive nameALX-0171 Nanobody
    D.3.9.4EV Substance CodeSUB117525
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboNebuliser solution
    D.8.4Route of administration of the placeboInhalation use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    RSV lower respiratory tract infection
    Infecciones del tracto respiratorio inferior por el virus respiratorio sincitial (RVS)
    E.1.1.1Medical condition in easily understood language
    RSV infection
    Infección por el virus respiratorio sincitial (RVS)
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level PT
    E.1.2Classification code 10061603
    E.1.2Term Respiratory syncytial virus infection
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the anti-viral effect and safety of different doses of inhaled ALX-0171 in subjects hospitalized for RSV lower respiratory tract infection.
    Evaluar el efecto antivírico y la seguridad de diferentes dosis de ALX-0171 inhalado en sujetos hospitalizados por infección del tracto respiratorio inferior por RSV.
    E.2.2Secondary objectives of the trial
    To evaluate the clinical activity, pharmacokinetic (PK) properties, pharmacodynamic (PD) effect and immunogenicity of different doses of inhaled ALX-0171.
    Evaluar la actividad clínica, las propiedades farmacocinéticas, el efecto farmacodinámico y la inmunogenia de diferentes dosis de ALX-0171 inhalado.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Subject is a male or female infant or young child aged 28 days to < 2 years with gestational age >/= 33 weeks.
    - Subject is otherwise healthy, but is hospitalized for and clinically diagnosed with RSV lower respiratory tract infection.
    - Subject has a positive RSV diagnostic test.
    - Subject is expected to have to stay in the hospital for at least 24 hours.
    - Parent(s)/legal guardian(s) provide written informed consent in accordance with locally approved consent process.
    - El sujeto es un lactante o niño de corta edad, esto es, de 28 días a <2 años, con una edad gestacional >/= 33 semanas, de sexo masculino o femenino.
    - El sujeto está por lo demás sano, pero es hospitalizado por diagnóstico clínico de infección del tracto respiratorio inferior por RSV.
    - El sujeto da positivo en una prueba diagnóstica del RSV.
    - El(los) progenitor(es)/tutor(es) legal(es) del sujeto otorga(n) el consentimiento informado por escrito de acuerdo con el proceso de consentimiento aprobado en el centro.
    E.4Principal exclusion criteria
    - Subject is known to have significant comorbidities
    - Subject is known to be HIV-positive (or if the child is <6 months of age, the mother is known to be HIV-positive).
    - Subject is known to be immunocompromised.
    - Subject has or is suspected to have an active, clinically relevant concurrent infection
    - Subject is critically ill and/or is expected to require invasive mechanical ventilation
    - Subject is currently participating in any other study with investigational drug or has received an investigational drug within 4 weeks or 5 half-lives of the concerned drug (whichever is longer) prior to screening
    - Subject was previously enrolled in a clinical study of ALX-0171
    - El sujeto presenta enfermedades concomitantes importantes.
    - El sujeto está infectado por el virus de la inmunodeficiencia humana (VIH) con seropositividad conocida (o, si el niño es menor de 6 meses, la madre es seropositiva).
    - El sujeto está inmunodeprimido.
    - El sujeto presenta una infección concomitante activa de importancia clínica, confirmada o de sospecha.
    - El sujeto se encuentra en estado crítico y/o se prevé que vaya a necesitar ventilación mecánica invasiva.
    - El sujeto participa en la actualidad en otro estudio con un fármaco en investigación o ha recibido un fármaco en investigación en el plazo de 4 semanas o 5 semividas del fármaco en cuestión (eligiéndose el plazo que sea mayor) antes de la selección.
    - El sujeto ha sido incluido con anterioridad en un estudio clínico de ALX-0171.
    E.5 End points
    E.5.1Primary end point(s)
    Anti-viral effect, as measured by the time needed for the viral load to drop below the assay quantification limit.
    Efecto antivírico en su determinación mediante el tiempo necesario para que la carga vírica disminuya por debajo del límite de cuantificación
    E.5.1.1Timepoint(s) of evaluation of this end point
    Throughout the in-hospital period, up to Day 14 after randomization
    Durante el periodo hospitalario, hasta el día 14 después de aleatorización
    E.5.2Secondary end point(s)
    - Safety assessment (assessed by physical examination, AEs, laboratory assessments and vital signs) of different doses of ALX-0171
    - Change from baseline in Global Severity Score
    - Time to clinical response
    - PK properties of ALX-0171
    - Viral load profile over time
    - Evaluation of serum anti-drug antibodies (ADA)
    - Evaluación de la seguridad (mediante exploración física, acontecimientos adversos, determinaciones de laboratorio y constantes vitales) de las diferentes dosis de ALX-0171
    - Variación respecto al momento basal de la puntuación global de severidad (Global Severity Score)
    - Tiempo hasta la respuesta clínica: definido como el tiempo entre la aleatorización y la consecución de una saturación de oxígeno adecuada y alimentación oral
    - Propiedades farmacocinéticas del ALX-0171
    - Perfil de la carga vírica a lo largo del tiempo en muestras de hisopado nasal (reacción en cadena de la polimerasa cuantitativa y método de placas)
    - Evaluación de anticuerpos antifármaco en suero
    E.5.2.1Timepoint(s) of evaluation of this end point
    Throughout the study, up to Day 28 after randomization
    Durante el estudio, hasta el día 2 después de aleatorización
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Phase 2b dose-ranging study
    Estudio fase 2b de búsqueda de dosis.
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned11
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA42
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    South Africa
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    last subject last visit
    última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months23
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months23
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 180
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F. of subjects for this age range: 180
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F. of subjects incapable of giving consent
    Infants and toddlers (28 days-23 months)
    Lactantes y niños de corta edad (28 días - 23 meses)
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state13
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 59
    F.4.2.2In the whole clinical trial 180
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After the end of the study, each subject will be treated according to standard clinical practice
    Al término del estudio, se administrará a cada sujeto el tratamiento adecuado según la práctica clínica habitual.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-10-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-09-14
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice